Teva settles further price-fixing lawsuits in the US

Teva's R&D labs in Netanya  credit: Teva PR
Teva's R&D labs in Netanya credit: Teva PR

Teva will pay a total of $450 million over six years to settle the cases.

Teva Pharmaceutical Industries (TASE: TEVA; NYSE: TEVA) has settled another lawsuit alleging price fixing in the US. Teva will pay $450 million in settlements approved by the court in the US, one of $425 million and the other of $25 million, without admitting wrongdoing. Payment of the settlement amounts will be spread over six years.

The first, larger settlement relates to a lawsuit filed by the US Department of Justice against Teva and other companies in 2020, alleging price fixing that led to overpayments totaling $350 million by US consumers. The allegation was that Teva used charities that assist patients in order to increase the use of its then flagship product, Copaxone, a treatment for multiple sclerosis. According to the prosecution, Teva made donations to these charities that would cover patients’ co-payments for Copaxone, in effect using the charities to pay kickbacks to patients for using the drug, contrary to the federal Anti-Kickback Statute. The alleged indirect result was a sharp rise in the price of Copaxone, from $17,000 a year in 2006 to $85,000 in 2017.

The second case, settled for $25 million, concerned further allegations of price fixing in the generic drugs industry. Two years ago, Teva reached a similar settlement in such a case, agreeing to pay a $225 million penalty and to sell pravastatin, a generic treatment for reducing cholesterol and triglycerides, to another company. In addition, Teva undertook to donate $50 million worth of two generic drugs, clotrimazole and tobramycin, to charity.

Two years ago, Teva also reached a settlement in the affair of the sale of opioids, painkillers that caused addiction in some half a million patients in the US. In that case, Teva agreed to pay compensation of $4.25 billion, $3 billion of it in cash.

In the past few years, Teva has taken action to settle many lawsuits, and also to reduce the high leverage that has weighed on it since it acquired Actavis, the generic drug division of Allergan, in 2015.

Since Teva announced the settlement of the opioids case two years ago, its share price has risen by more than 170%, bringing it to a market cap of NIS 75 billion, although this is still far below its peak value of NIS 250 billion.

In this morning’s trading on the Tel Aviv Stock Exchange, Teva’s share price is down 1.55%, at NIS 65.26.

Published by Globes, Israel business news - en.globes.co.il - on October 13, 2024.

© Copyright of Globes Publisher Itonut (1983) Ltd., 2024.

Teva's R&D labs in Netanya  credit: Teva PR
Teva's R&D labs in Netanya credit: Teva PR
Unframe founders credit: Yossi Yarom Israeli AI enterprise platform co Unframe raises $50m

Unframe’s turnkey AI solutions enable companies to solve any enterprise AI use case at scale with fully functional, customized AI solutions for businesses in a matter of hours, rather than months.

Combatica credit: Combatica Combatica launches next-gen VR AI training platform

The Israeli company's virtual reality platform includes 50 AI generated scenarios, seven maps and even situations for operating night vision.

Shekel credit: Shutterstock Vladirina 32 Shekel volatility after US tariffs announcement

The shekel is weakening sharply against the euro, which is gaining following the unveiling of Donald Trump's tariffs plan.

Minister of Finance Bezalel Smotrich credit: Noam Moskovitz Knesset Spokesperson Treasury assesses potential damage to Israel's US exports

Israel will be charged a higher tariff on its exports to the US - its biggest export customer - than Turkey and the UAE.

Iranian flag credit: Shutterstock Why inflation haunts Iran

With a month-on-month increase of 3.3% and an annual rate of 37.1%, inflation reflects the struggles of millions of Iranians.

APM merges with lawyers from Doron, Tikotzky Kantor, Gutman credit: Eyal Merilos APM merges with 12 lawyers from Doron, Tikotzky Kantor, Gutman

With the addition of these 12 lawyers, Amit Pollak Matalon & Co. will now have 135 lawyers.

US President Donald Trump credit: Reuters Sipa USA Israel on list as Trump unveils tariffs

Relatively low reciprocal tariffs will be imposed on Israeli goods sold in the US.

Deflated unicorn credit: Shutterstock Big Tech 50 reports more huge falls in startup valuations

Israeli R&D partnership Big Tech 50 reports that an investment of $2 million in Orcam made in 2021, shrank to just $31,000 at the end of 2024.

NextFerm technologies based on yeast credit: NextFerm Food-tech co NextFerm suspends operations

The company, which produces food ingredients in yeast without genetic engineering, cannot pay its debts and is seeking a buyer.

Minister of Finance Bezalel Smotrich credit: Shlomi Yosef OECD sees recovery in growth but high inflation

The OECD Israel Economic Survey 2025 recommends that the Israeli government take several restraining measures, in order to exit the economic storm created by the war.

Dano Ben-Hur credit: Dror Sithakol Statisticians contradict BoI on impact of housing finance deals

The Central Bureau of Statistics insists the impact of 20/80 buy now pay later financing deals on the real estate market and housing prices is minimal.

Governor of the Bank of Israel Amir Yaron  credit: Government Press Office Debt fears top Bank of Israel's concerns

Most unusually, Governor of the Bank of Israel Amir Yaron's press conference last week did not focus on inflation and the impending interest rate decision.

US President Donald Trump  credit: Reuters/Leah Millis Israel moves to avoid Trump's tariffs axe

Minister of Finance Bezalel Smotrich has signed an order canceling all tariffs on imports from the US. The impact will mostly be on agricultural produce.

Forbes Rich List credit: Shutterstock Maslowski Marcin Wiz founders ranked in Forbes 2025 Rich List

There are a few dozen Israelis listed in the 2025 Forbes Real-Time Billionaires List including Wiz founders Assaf Rappaport, Yinon Costica, Roy Reznik and Ami Luttwak.

SatixFy CEO Nir Barkan credit: Ariel Barkan Canada's MDA Space to buy Israeli satcom co SatixFy

MDA Space will pay $269 million for the Israeli company, including taking on a $76 million debt and a 75% premium on SatixFy's closing price on Nasdaq yesterday.

Raising dollars credit: Shutterstock Israeli startups raised over $1b in March

Israeli privately-held tech companies have raised $2.1 billion in the first three months of 2025, according to IVC-LeumiTech, up 24% from the corresponding quarter of 2024.

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018